Reference:USA 21 CFR Part 312 09-Apr-2025 § 312.40 (c) (d)
From GxPlex
| Document information | |
|---|---|
| Reference | USA 21 CFR Part 312 09-Apr-2025 |
| Validity area | USA |
| Scope(s) | HM |
| Document name | 21 CFR Part 312 |
| Version / Revision | 09-Apr-2025 |
| Status | Current |
| Document type | Legal act |
| Language(s) | EN |
| Description | Title 21 —Food and Drugs
Chapter I —Food and Drug Administration, Department of Health and Human Services Subchapter D—Drugs for Human Use Part 312 Investigational New Drug Application https://www.ecfr.gov/current/title-21 |
| Official source | Official link |
| Restricted access | No |
| Submitted by | Florian Adragna |
| Contributors | |
| Reference Details | |
|---|---|
| Module | Module 3 — Unit 3.4.2 |
| Scope | HM |
| Document part | § 312.40
(c) (d) |
| Language | EN |
| Original entry by | Florian Adragna |
| Contributors | |
| Tags | Investigational drug (IMP), Sponsor, Requirements, FDA |
Content
§ 312.40 General requirements for use of an investigational new drug in a clinical investigation. […] (c) A sponsor may ship an investigational new drug to investigators named in the IND: (1) Thirty days after FDA receives the IND; or (2) On earlier FDA authorization to ship the drug. (d) An investigator may not administer an investigational new drug to human subjects until the IND goes into effect under paragraph (b) of this section.
